Primary course vaccination is recommended for all adolescents aged 12 – <18 years. The recommended schedule for the primary course is 2 doses, 8 weeks apart. An additional (3rd) primary course dose is recommended for severely immunocompromised adolescents, which should be given 8 weeks after the second dose.
After completing a primary course, a 2023 dose can be considered for adolescents who have medical comorbidities that increase their risk of severe COVID-19 or disability with significant or complex health needs, and whose last COVID-19 vaccine dose was 6 months ago or longer.
Children and adolescents who become eligible to consider a 2023 dose can continue to receive this dose until updated advice becomes available in 2024.
Omicron XBB.1.5-based vaccines are preferred for the primary course and for further doses in this age group. People aged ≥12 years can receive Comirnaty Omicron XBB.1.5 ≥12 years formulation (dark grey cap) and Spikevax Omicron XBB.1.5. Comirnaty bivalent Original/Omicron BA.4/5, Spikevax bivalent Original/Omicron BA.4/5, and Nuvaxovid Original can also be used for primary or further doses but are not preferred.